Gelesis Holdings Market Cap 2021-2022 | GLS
Gelesis Holdings market cap history and chart from 2021 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Gelesis Holdings market cap as of February 03, 2023 is $0.02B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.024B | $0.011B |
| Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $158.293B | 9.67 |
| GSK (GSK) | United Kingdom | $71.300B | 9.41 |
| Bio-Rad Laboratories (BIO.B) | United States | $12.069B | 28.64 |
| QIAGEN (QGEN) | Netherlands | $11.249B | 19.20 |
| Ginkgo Bioworks Holdings (DNA) | United States | $3.996B | 0.00 |
| Myovant Sciences (MYOV) | United Kingdom | $2.614B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.485B | 22.29 |
| Biohaven (BHVN) | United States | $1.240B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.697B | 5.48 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.356B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.070B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.070B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.024B | 0.00 |
